Radioiodinated methylene blue for melanoma targeting: chemical characterisation and tumour selectivity of labelled components.
Radioiodinated methylene blue contains a mixture of components showing selective uptake in human pigmented melanoma, and it has potential for imaging and therapy. Nuclear magnetic resonance and mass spectroscopic studies show that the majority of the radioactivity (85%) is in the form of monoiodinated methylene blue, 4-iodo-3-methylamino-7-dimethylaminophenaza thionium chloride. The amino group ortho-to iodine has become demethylated to a mono-methylamino group. The remainder (15%) of the mixture is the doubly labelled 4,5-diiodo-3,7-bis(methylamino) phenazathionium chloride. The separated components show similar tumour selectivity in athymic mice bearing human pigmented melanomas.
Blower
P J
PJ
Nuclear Medicine Department, Kent and Canterbury Hospital, UK.
Clark
K
K
Link
E M
EM
D000818:Animals; D006801:Humans; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D009682:Magnetic Resonance Spectroscopy; D008545:Melanoma / Q000175:diagnosis*; D008751:Methylene Blue / Q000378:metabolism*; D051379:Mice
D007457:Iodine Radioisotopes; D008751:Methylene Blue